Float Short %

23.24

Margin Of Safety %

Put/Call OI Ratio

0.22

EPS Next Q Diff

0.4

EPS Last/This Y

-0.92

EPS This/Next Y

-0.46

Price

31.04

Target Price

92.94

Analyst Recom

1.11

Performance Q

-17.82

Upside

-233.2%

Beta

0.76

Ticker: VKTX

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-01-23	VKTX	32.22	0.26	0.46	173277
2026-01-26	VKTX	31.74	0.27	0.30	156503
2026-01-27	VKTX	31.45	0.27	0.10	159556
2026-01-28	VKTX	30.53	0.26	0.21	161801
2026-01-29	VKTX	30.25	0.26	0.19	166080
2026-01-30	VKTX	29.08	0.26	0.43	167263
2026-02-02	VKTX	29.92	0.26	0.14	156374
2026-02-03	VKTX	29.45	0.26	0.13	163333
2026-02-04	VKTX	29.54	0.26	0.12	168914
2026-02-05	VKTX	26.28	0.25	0.26	175400
2026-02-06	VKTX	28.18	0.24	0.20	178083
2026-02-09	VKTX	29.31	0.24	0.11	166568
2026-02-10	VKTX	28.74	0.24	0.28	170498
2026-02-11	VKTX	28.56	0.24	0.17	171677
2026-02-12	VKTX	30.52	0.24	0.29	184455
2026-02-13	VKTX	29.03	0.24	0.36	188487
2026-02-17	VKTX	30.44	0.23	0.24	176210
2026-02-18	VKTX	30.07	0.23	0.53	184977
2026-02-19	VKTX	31.12	0.23	0.10	186045
2026-02-20	VKTX	31.03	0.22	0.23	186789
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-01-23	VKTX	32.22	-181.2	-	-2.61
2026-01-26	VKTX	31.76	-181.2	-	-2.61
2026-01-27	VKTX	31.40	-181.2	-	-2.61
2026-01-28	VKTX	30.42	-181.2	-	-2.61
2026-01-29	VKTX	30.27	-181.2	-	-2.61
2026-01-30	VKTX	29.05	-181.2	-	-2.61
2026-02-02	VKTX	29.92	-181.2	-	-2.61
2026-02-03	VKTX	29.44	-181.2	-	-2.61
2026-02-04	VKTX	29.56	-181.2	-	-2.61
2026-02-05	VKTX	26.29	-181.2	-	-2.61
2026-02-06	VKTX	28.43	-181.2	-	-2.61
2026-02-09	VKTX	29.31	-181.2	-	-2.61
2026-02-10	VKTX	28.73	-181.7	-	-2.61
2026-02-11	VKTX	28.56	-181.7	-	-2.61
2026-02-12	VKTX	30.52	-181.7	-	-2.61
2026-02-13	VKTX	29.23	-142.9	-	-4.28
2026-02-17	VKTX	30.44	-141.1	20.1	-4.22
2026-02-18	VKTX	30.13	-133.4	46.9	-4.11
2026-02-19	VKTX	31.10	-133.4	-	-4.11
2026-02-20	VKTX	31.04	-133.4	-	-4.11
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-01-23	VKTX	-12.49	-3.39	22.19
2026-01-26	VKTX	-12.49	-3.31	22.19
2026-01-27	VKTX	-12.49	-3.31	22.19
2026-01-28	VKTX	-12.49	-3.31	22.91
2026-01-29	VKTX	-12.49	-3.31	22.91
2026-01-30	VKTX	-12.49	-3.31	22.91
2026-02-02	VKTX	-12.49	-3.47	22.91
2026-02-03	VKTX	-12.49	-3.47	22.91
2026-02-04	VKTX	-12.49	-3.47	22.91
2026-02-05	VKTX	-12.49	-3.47	22.91
2026-02-06	VKTX	-12.49	-3.47	22.91
2026-02-09	VKTX	-12.49	-3.44	22.91
2026-02-10	VKTX	-12.49	-3.44	22.91
2026-02-11	VKTX	-12.49	-3.44	23.76
2026-02-12	VKTX	-12.49	-3.44	23.76
2026-02-13	VKTX	-12.49	-3.44	23.76
2026-02-17	VKTX	-12.26	-2.05	23.24
2026-02-18	VKTX	-12.25	-2.05	23.24
2026-02-19	VKTX	-12.25	-2.05	23.24
2026-02-20	VKTX	-12.25	-2.05	23.24
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-1.38

Avg. EPS Est. Current Quarter

-0.96

Avg. EPS Est. Next Quarter

-0.98

Insider Transactions

-12.25

Institutional Transactions

-2.05

Beta

0.76

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

68.8

Max Drawdown 5-Year %

-78.9

Target Price

92.94

P/E

Forward P/E

PEG

P/S

P/B

5.57

P/Free Cash Flow

EPS

-3.18

Average EPS Est. Cur. Y

-4.11

EPS Next Y. (Est.)

-4.57

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.59

Return on Equity vs Sector %

-85.3

Return on Equity vs Industry %

-67.8

EPS 1 7Days Diff

-0.4

EPS 1 30Days Diff

-0.4

EBIT Estimation

Viking Therapeutics, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 53

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

stock quote shares VKTX – Viking Therapeutics, Inc. Stock Price stock today

news today VKTX – Viking Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch VKTX – Viking Therapeutics, Inc. yahoo finance google finance

stock history VKTX – Viking Therapeutics, Inc. invest stock market

stock prices VKTX premarket after hours

ticker VKTX fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: VKTX

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y